Pen or syringe? study tests easier pasireotide delivery
NCT ID NCT07312643
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving the drug pasireotide with a reusable pen works as well as using a traditional syringe. Forty healthy adults received a single dose by both methods to compare how the drug enters the body and if it is safe. The goal is to find a more convenient way for patients to take this medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pasireotide
- What this could lead to
- If successful, this could show that a reusable pen is a safe and effective way to deliver pasireotide, potentially making it easier for patients to use.
- What could go wrong
- This is an early-phase study in healthy volunteers, not patients. It only tests how the drug is absorbed, not whether it works for any disease. The pen may not perform as well as the syringe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nuvisan GmBH
Neu-Ulm, 89231, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a natural antibody quiet inflammation? a new trial investigates
- Can a simple calcium tablet help prevent postpartum bleeding?
- Can a two-drug combo better tame prostate trouble?
- First human trial launches for Hemay5259: a new Extended-Release drug candidate
- Apples' hidden power: study probes how polyphenols scavenge harmful carbonyls
- New vaginal capsule aims to tackle stubborn bacterial vaginosis